TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7144047
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups underwent treatment based on diet and increased physical exercise for two years
Study: 26057484
Drug: Collagen/thrombin/autologous platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen/thrombin/autologous platelet haemostatic agent
Study: 21469388
Drug: gelatin sponge
Normalized name: ABSORBABLE GELATIN SPONGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin sponge patch bonded repair group
Study: 19460684
Drug: Inhaled dornase
Normalized name: dornase alfa Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dornase alfa administered 30 minutes before airway clearance therapy (ACT)
Study: 19460684
Drug: Inhaled dornase
Normalized name: dornase alfa Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dornase alfa administered before bedtime or upon awakening
Study: 19460684
Drug: Inhaled dornase
Normalized name: dornase alfa Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dornase alfa
Study: 17011315
Drug: Baclofen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (0.5 mg/kg)
Study: 15279069
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg, po)
Study: 3113975
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg orally at bedtime)
Study: 3113975
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg at bedtime)
Study: 3113975
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg) and gonadotropin releasing hormone (100 micrograms)
Study: 7509570
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (estradiol transdermal system [Estraderm TTS] plus chlormadinone)
Study: 7509570
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (verapipride)
Study: 3281619
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus a diuretic
Study: 3281619
Drug: Monotherapy (unspecified)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (unspecified)
Study: 10674115
Drug: Inhalable heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalable heroin (combined with oral methadone), administered seven days per week, three times per day for a period of six to twelve months.
Study: 10674115
Drug: Injectable heroin
Normalized name: heroin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable heroin (combined with oral methadone), administered seven days per week, three times per day for a period of six to twelve months.
Study: 8224265
Drug: Flutamide 500
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 500 mg/d
Study: 3317340
Drug: Captopril (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50-100 mg/day) and Verapamil (160-240 mg/day)
Study: 26740194
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 g plus nasal irrigation
Study: 12512664
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment using air abrasion followed by placement of preventive resin restorations
Study: 9809925
Drug: Carvedilol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (2.5 mg once a day)
Study: 9809925
Drug: Metoprolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (30 mg once a day)
Study: 9809925
Drug: Doxazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (0.5 mg once a day)
Study: 7806412
Drug: One-appointment root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-appointment root canal therapy using calcium hydroxide
Study: 7806412
Drug: Two-appointment root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-appointment root canal therapy using calcium hydroxide
Study: 2528492
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin infusion (0.7 mU kg‐1 min‐1 for 8 hours)
Study: 2528492
Drug: 0.15 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mmol/l NaCl solution infusion over 8 hours (Control)
Study: 2528492
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Human insulin and NaCl)
Study: 4804455
Drug: Fenfluramine treatment
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine treatment without dietary restriction
Study: 31630445
Drug: Weekly adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly adalimumab (ADAew)
Study: 23750742
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone and brief behavioral counseling
Study: 21347224
Drug: pSG2.HBs vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: pSG2.HBs vaccine followed by MVA.HBs vaccine
Study: 21347224
Drug: 3TC therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3TC therapy
Study: 21347224
Drug: Prime-boost vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prime-boost vaccine regimen (pSG2.HBs and MVA.HBs)
Study: 21347224
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Intramuscular rabies vaccine)
Study: 18645683
Drug: SK3530 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK3530 (50, 100, or 150 mg)
Study: 16497479
Drug: Gelclair (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelclair (15 ml applied directly onto the wound 3 times per day, 1 hour before meals for 1 week)
Study: 16497479
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg 3 times per day for 4 days)
Study: 10225169
Drug: Tramadol 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 3.0 mg kg‐1
Study: 10225169
Drug: Pethidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 1.5 mg kg‐1
Study: 10225169
Drug: Nalbuphine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.3 mg kg‐1
Study: 10225169
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 0.02 ml kg‐1)
Study: 8934303
Drug: Codeine 25
Normalized name: codeine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 25 mg
Study: 12799847
Drug: Codeine 50
Normalized name: codeine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 50 mg
Study: 8934303
Drug: Codeine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (both doses)
Study: 8934303
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Codeine
Study: 1882280
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: All drugs given simultaneously once weekly for 15 days
Study: 27043756
Drug: Shape Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape Program intervention (12-month digital health treatment)
Study: 23114016
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus probiotics (Probinul - Cadigroup)
Study: 19783805
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy alone
Study: 19639462
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (100 mg twice a day)
Study: 17478172
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) leuprolide acetate
Study: 12150492
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once-daily
Study: 7924363
Drug: Carbicarb (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbicarb (1 mEq sodium/mL, n = 18)
Study: 7924363
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (1 mEq sodium/mL, n = 18)
Study: 2685445
Drug: Intracoronary thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary thrombolytic therapy with avelysine
Study: 2685445
Drug: Systemic thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic thrombolytic therapy with streptodekase
Study: 21130990
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 μg
Study: 15517308
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of alphaS1‐casein hydrolysate (TS)
Study: 12390521
Drug: Sera containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sera containing anti-L-periaxin antibody injected into the endoneurium of rat sciatic nerve
Study: 12390521
Drug: Sera containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sera containing anti-L-periaxin antibody
Study: 12390521
Drug: Depleted sera
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depleted sera of anti-L-periaxin antibodies
Study: 9916056
Drug: Vibrio cholerae
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrio cholerae 638 (El Tor, Ogawa) strain, doses ranging from 4 x 10(7) to 2 x 10(9) vibrios.
Study: 7574044
Drug: Low-dose acadesine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acadesine (0.05 mg.kg‐1.min‐1)
Study: 7574044
Drug: High-dose acadesine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acadesine (0.1 mg.kg‐1.min‐1)
Study: 2076720
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide 5 mg
Study: 31769212
Drug: Ustekinumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (6 mg/kg intravenous infusion at week 0, then 90 mg subcutaneous injections every 8 weeks starting at week 8)
Study: 30583949
Drug: Centrifuged adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifuged adipose tissue (CAT) treatment
Study: 30583949
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no CAT treatment)
Study: 25566704
Drug: Continuous presternal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous presternal bupivacaine infusion (5 mL/h bupivacaine 0.25%)
Study: 20071288
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg tablets
Study: 17284136
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (mean dose 64.0 ± 23.3 mg, 0.75 mg/kg)
Study: 28671712
Drug: Rifaximin 550-mg
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550-mg BD (n=36)
Study: 24917547
Drug: AZD3839 single-ascending-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3839 single-ascending-dose (SAD) study
Study: 20551828
Drug: Written disclosure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written disclosure therapy (WDT) group
Study: 19073509
Drug: Tamoxifen (T)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (T) 20 mg per day orally
Study: 19073509
Drug: Exemestane (E)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (E) 25 mg per day orally
Study: 9536229
Drug: Near erythemogenic
Normalized name: OCTINOXATE 3.5 mg in 1 mL / TITANIUM DIOXIDE 1.9 mg in 1 mL TOPICAL LIQUID [Revlon Nearly Naked Makeup]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near erythemogenic therapy (70% of the 311 nm MED)
Study: 9536229
Drug: Far erythemogenic
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Far erythemogenic therapy (35% of the 311 nm MED)
Study: 9536229
Drug: Near erythemogenic
Normalized name: OCTINOXATE 3.5 mg in 1 mL / TITANIUM DIOXIDE 1.9 mg in 1 mL TOPICAL LIQUID [Revlon Nearly Naked Makeup]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near erythemogenic therapy
Study: 9536229
Drug: Far erythemogenic
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Far erythemogenic therapy
Study: 40345
Drug: mequitazine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: mequitazine (two 10‐milligram doses a day)
Study: 40345
Drug: dexchlorpheniramine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexchlorpheniramine (two 12‐milligram doses a day)
Study: 19561256
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bevacizumab treatment)
Study: 16249974
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg b.i.d. + amoxicillin 1,000 mg + clarithromycin 500 mg (14 days)
Study: 16249974
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg b.i.d. + amoxicillin 1,000 mg + clarithromycin 500 mg (14 days)
Study: 16249974
Drug: pantoprazole +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole + amoxicillin + clarithromycin
Study: 16249974
Drug: lansoprazole +
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lansoprazole + amoxicillin + clarithromycin
Study: 11346934
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy in combination with lumpectomy and axillary dissection
Study: 11346934
Drug: Excision plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excision plus radiation therapy
Study: 9692697
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine (bolus 20 mg, continuous infusion 4 mg/h)
Study: 26834213
Drug: Baricitinib 4/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4/8 mg
Study: 26834213
Drug: Baricitinib <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib < 4 mg
Study: 23638770
Drug: Ultrabiotique(®) (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrabiotique(®) (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantarum and Bifidobacterium breve) administered daily for 7 days
Study: 20607528
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese herbs (Astragalus membranaceus, Salvia miltiorrhiza, and a decoction of six drugs)
Study: 16584945
Drug: Motion palpation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion palpation (MP) by team A (experienced chiropractor palpating, inexperienced performing treatment)
Study: 16584945
Drug: Motion palpation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion palpation (MP) by team B (inexperienced chiropractor palpating, experienced performing treatment)
Study: 8837559
Drug: c7E3 (glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: c7E3 (glycoprotein IIb/IIIa antibody) - bolus and 12-hour infusion
Study: 1430630
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of intravenous drug use (IVDU)
Study: 3781687
Drug: L-acetylcarnitine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine therapy (two 500 mg tablets t.i.d. for 40 days)
Study: 26799373
Drug: Active stimulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active stimulation (Treatment group)
Study: 26799373
Drug: Active stimulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active stimulation (Treatment group) during partial crossover
Study: 25255578
Drug: Fructose (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (0.75 g/kg bodyweight)
Study: 18812323
Drug: Adjunctive device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive device (catheter thrombus aspiration)
Study: 18812323
Drug: Adjunctive device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive device (mechanical thrombectomy)
Study: 18812323
Drug: Adjunctive device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive device (embolic protection)
Study: 18812323
Drug: Adjunctive device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive device (all types)
Study: 15262828
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel loading dose in first-use group
Study: 15262828
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel loading dose in chronic therapy group
Study: 15262828
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel loading dose in both groups
Study: 7967421
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose of 30 Gy in group 1 (stages I, IIA)
Study: 7967421
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose of 25 Gy in group 2 (stages IIEA, IIB, IIIA)
Study: 7967421
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose of 20 Gy in group 3 (stages IIEB, IIIB, IV)
Study: 3668844
Drug: Ethanol (67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (67 g)
Study: 3668844
Drug: Ethanol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0, 22, 45 g) and Diazepam (0, 10, 20 mg)
Study: 30761720
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100 (IGlar U100)
Study: 26544853
Drug: MVA-B vaccine
Normalized name: MVA-BN-brachyury-TRICOM vaccine
DrugBank: MVA-BN-brachyury-TRICOM vaccine (DB17424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-B vaccine (3 intramuscular injections)
Study: 24565243
Drug: Propofol-fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-fentanyl (1 μg.kg(‐1) fentanyl, 1mg.kg(‐1) propofol)
Study: 24565243
Drug: Propofol-alfentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-alfentanil (10 μg.kg(‐1) alfentanil, 1mg.kg(‐1) propofol)
Study: 21601286
Drug: Systematic Treatment
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
Study: 17127572
Drug: Conventional dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressing therapy (baseline phase)
Study: 11360125
Drug: Iron (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (60 mg elemental iron/day) + albendazole (200 mg/day for 3 consecutive days, repeated 1 month later)
Study: 11360125
Drug: Albendazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (200 mg/day for 3 consecutive days, repeated 1 month later)
Study: 8424504
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg epidural morphine + 75 mg IM diclofenac
Study: 8424504
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg epidural morphine + 75 mg IM diclofenac
Study: 8424504
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine + 75 mg IM diclofenac
Study: 8424504
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg epidural morphine + 75 mg IM diclofenac
Study: 8424504
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine + 75 mg IM diclofenac
Study: 8424504
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine + 3 mL normal saline IM
Study: 3566307
Drug: Cisplatin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (10-20 mg/m2 i.v., on days 1-5 or 50-100 mg/m2 i.v., on day 1, every 3 to 4 weeks)
Study: 29281036
Drug: Iclaprim 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim 80 mg intravenously every 12 hours for 5-14 days
Study: 29281036
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg intravenously every 12 hours for 5-14 days
Study: 27428533
Drug: Self-massage at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-massage at the musculotendinous junction for 3 min daily, five times per week, for 12 weeks
Study: 22351480
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg MG
Study: 22351480
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg MG (thrice a day for 1 week)
Study: 18374423
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus sibutramine (10‐20 mg)
Study: 11777716
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate ophthalmic suspension 0.5%
Study: 9651632
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine 1
Study: 9651632
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine 2